Silodosin Versus Tamsulosin for Treatment of Ureteral Stones

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ureteral calculi, commonly known as kidney stones, are a frequent cause of Emergency Department (ED) visits. These stones can get caught in the ureter (the tube connecting the kidney to the bladder) and cause symptoms including pain, nausea, and vomiting. As long as the obstructing stone meets certain conditions and the patient isn't too sick, the patient is usually sent home to try and pass the stone without surgery. This treatment is known as medical expulsive therapy (MET), and routinely involves the use of a drug called tamsulosin, which relaxes the smooth muscle of the urinary system to help the stone pass. Silodosin is a drug in the same class of tamsulosin, but which is thought to have a more selective action and a quicker onset, which would theoretically make it better for aiding in kidney stone passage. The purpose of this study is a head-to-head, blinded comparison of these two drugs to see how quickly they result in stone passage. Subjects are patients presenting to the ED with acute kidney stone shown by CT scan, and who are appropriate for MET. The main study intervention is randomization to receiving either tamsulosin or silodosin. The hypothesis is that silodosin will have decreased time to stone passage compared to tamsulosin.

Subjects who qualify and consent are randomized to a two-week course of either silodosin or tamsulosin. They are also given prescriptions for standard of care medications for pain and nausea, as well as a pain diary. They receive a follow-up phone call after one week to remind them of their follow-up appointment, ask about adverse events, and determine if their stone has passed. They have a follow-up visit with study staff at the end of their two week treatment to collect their pain diary, pill count, adverse events, and to determine if their stone has passed. Study participation ends after this follow-up visit.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy

NCT01560091

Kidney Stones

WITHDRAWN PHASE3

Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi

NCT05977647

Ureteric Stone of Lower Third of Ureter

COMPLETED PHASE4

Comparative Study for Medical Therapy for Lower Ureteral Stones

NCT06707181

Lower Ureteral Stones

COMPLETED PHASE3

Comparison of Silodosin and Tamsulosin for Medical Expulsive Therapy in Patients With Ureteral Stones

NCT06999135

Tamsulosin Silodosin Medical Expulsive Therapy

COMPLETED NA

Effectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm.

NCT02090439

Kidney Stone Expulsive Medical Therapy

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Procedures Involved in the Research. This study is a prospective, randomized, double-blinded, head-to-head trial comparing two medications. Patients with symptoms of renal colic who present to the emergency department will be evaluated by the ED staff as per usual routine. After a work-up (including routine chemistry, complete blood count, urine analysis, urine culture, and non-contrast CT scan of the abdomen and pelvis) has been completed, patients who meet inclusion criteria will be asked whether they are willing to enroll in the study. Those who are unsuitable for the study or unwilling to participate will continue to receive routine care for their ureteral calculus. Those who consent will be enrolled as subjects in the study, and given a 2-week supply of either tamsulosin or silodosin in blinded bottles with the appropriate dosing instructions. The prescriptions will be dispensed by the pharmacy; therefore the subjects and study staff will be blinded to which prescription the subject receives. Randomization will be done in advance and a key made to correlate subject enrollment number with which prescription they have received. Throughout the study, the study staff will make no efforts to ascertain which medication the subject has been given, unless an adverse event is suspected. Each participant will be given an information card that details the two possible medications they are taking, which can be presented to their physicians as needed.

Subjects will then be discharged to home as per routine care with instructions to drink plenty of fluids, and will be given a strainer and asked to attempt to catch their ureteral calculus. They will also be given a standardized prescription analgesic package (Percocet 5/325mg #20, Motrin 600mg #60, Zofran OD 4mg #20 with standard dosing instructions) and a Visual Analog Pain Scale diary to be filled out daily. Subjects will be given standardized discharge instructions as per standard of care that will include indications for immediate ED return for signs and symptoms of infection or MET failure (fever, worsening pain, vomiting, lethargy, unsteadiness, syncope or inability to tolerate oral pain medications). As per standard of care, they will be instructed to return to the ER immediately if they develop any of these symptoms. Finally, the subject's contact information will be collected at the time of enrollment and a follow-up appointment will be scheduled for them with Urology in 4 weeks to ensure they get appropriate and timely specialty follow-up. This follow-up is also standard of care, and will occur after the subject's participation in the study ends.

Each subject will be scheduled to return to the ER in 2 weeks to be seen by the research staff for data collection. They will be asked to bring their pill bottle and visual analog pain scale diary to this visit. If the subject reports having passed a stone consistent with their initial imaging, or have resolution of their pain to suggest they passed the stone unseen, this will conclude their participation in the study. However, if they are still having symptoms, their case will be categorized as an outpatient treatment failure and the subject will be registered to be seen by an ER Physician and a Urology consult will be ordered, concluding their participation in the study. This is current standard of care, and will be covered by insurance. Any subject that has an unscheduled visit to an ER for a ureterolithiasis-related complaint will also be considered an outpatient treatment failure. This will also conclude their participation in this study.

To ensure follow-up, subjects will be called one week after enrollment. They will be reminded of their 2-week follow-up appointment and the need to bring in their pill bottles. Each subject will also be asked if they have passed the stone or had resolution of the pain. The will be reminded that they must follow-up even if they are no longer having symptoms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ureteral Calculus Ureterolithiasis Ureteral Stone

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Silodosin

Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.

Group Type ACTIVE_COMPARATOR

Silodosin

Intervention Type DRUG

8mg tablet, 1 tab PO daily for 2 weeks

Tamsulosin

Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.

Group Type ACTIVE_COMPARATOR

Tamsulosin

Intervention Type DRUG

0.4 mg Tab, 1 tab PO daily for 2 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Silodosin

8mg tablet, 1 tab PO daily for 2 weeks

Intervention Type DRUG

Tamsulosin

0.4 mg Tab, 1 tab PO daily for 2 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rapaflo Flomax

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults age 18 to 70 years
* Non-diabetic
* Unilateral ureteral calculus 4 to 10 mm visible on CT scan within the ureter
* Serum creatinine level within normal range
* Ability to tolerate oral fluids and oral pain medication
* Ability to make informed medical decisions regarding consent
* Willingness to follow up in the ER in two weeks

Exclusion Criteria

* Adults unable to consent
* Age \<18
* Signs of infection including Temperature \>38º C or Urinalysis with any of the following: Positive Leukocyte Esterase, Positive Nitrates, or White Blood Cell Count \>5/hfp in the setting of a positive urine culture (defined as a single isolated bacterial species population of \>100,000 CFU)
* Patients with chronic pain already undergoing treatment with narcotic medications
* Patients already taking an alpha adrenergic antagonist medication
* Pregnant women
* Prisoners
* No working phone number

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No